Guilin Sanjin Pharmaceutical Co., Ltd announced that on July 5th, it signed a contract with Dragonfly Sciences, Inc., a United States-based company, to acquire a 100% stake in a Shanghai-based pharmaceutical technology company, which is engaged in the research and development of biopharmaceutical products, drugs, pharmaceutical intermediates, and medical equipment, for $3.5 million.